Chordia Therapeutics, Simbio Pharmaceuticals, etc.

<190A> Chordia Therapeutics Co., Ltd. SBI Investment Co., Ltd. shareholding ratio 6.42% → 8.73% Reporting obligation start date 2024/07/18 <202A> Mamezou Digital Holdings Co., Ltd. Mamezou K2 Top Holdings Co., Ltd. shareholding ratio 71.78% → 67.99% Reporting obligation start date 2024/07/24 <2164> Regional Newspaper Co., Ltd. Engi Co., Ltd.

Fisco Japan19:35 ET

It is a strong and easy to buy on dips, but there is a heavy resistance to upward movement.

[Emerging Markets Individual Stock Strategies] Today's emerging markets are expected to have a solid development. In the US stock market on the 25th yesterday, the Dow Jones Industrial Average rebounded for the first time in three days, up 81.20 points (+0.20%) to 39,935.07 points. The pessimistic view on the economy has retreated due to the better-than-expected growth in domestic GDP in the April-June quarter, which supported the stock prices. However, the profit-taking selling ahead of the announcement of the important inflation indicators restrained the upside, and the high-tech sector was weak and slowed down towards the end, with the Nasdaq composite index...

Fisco Japan19:20 ET

List of stocks with cleared clouds (Part 2) [Ichimoku Kinko Hyo: List of Stocks with Cleared Clouds]

List of breakthrough stocks under the clouds in the market, Code Company Name Closing Price Leading Span A Leading Span B, Tokyo Stock Exchange Prime, <1860> Toda Construction 1044 1057.75 1045 <1871> PS 991 999.75 1003.5 <1885> Toa Construction 975 995 1029.5 <1939> Yondenko

Fisco Japan19:05 ET

Kinciro, Sunbio, and other emerging market press releases.

<3727> APLIX has completed the buyback of its own shares. <4013> Kinjiro raises upward revision, with the first half operating profit expected to be 0.281 billion yen, up from 0.188 billion yen. <4588> OncoTherapy Science will issue a large number of shares exercised from the 20th subscription rights (with exercise price adjustment clause) starting from the 2nd, with a total of 0.57 million 1500 shares issued. <4592> SanBio's new patent has been approved in the United States for cell therapy for chronic cerebral infarction using the main development product SB623.

Fisco Japan18:26 ET

Fujitsu has turned a profit in the first quarter with a profit and loss of 21.3 billion yen.

Fujitsu (6702) announced that its Q1 financial results for the fiscal year ending March 2025 showed sales revenue of 830.03 billion yen, a 3.8% increase YoY, and operating profit of 21.387 billion yen (compared to a loss of 1.88 billion yen in the same period last year), exceeding the consensus estimate of about 1.77 billion yen. The company's main IT services business, driven by the DX demand, performed well domestically. For the fiscal year ending March 2025, sales revenue is expected to be 3,760 billion yen, a slight increase of 0.1% over the previous year, and operating profit is expected to increase by 16.3%, reaching 330 billion yen.

Fisco Japan17:18 ET

Against the background of a decline in US stocks and a strengthening yen, the price falls below 38,000 yen.

The Nikkei average fell significantly for the seventh consecutive business day. With a drop of 1,285.34 yen, it closed the trading day at 37,869.51 yen (with a volume estimate of 2.1 billion 10 million shares), falling below the 38,000 yen mark for the first time in about three months since April 26. The negative investor sentiment was due to the sell-off of high-tech stocks in the US market the day before, as well as the appreciation of the yen, which accelerated to 1 dollar = 152 yen, the highest in about two and a half months, and affected a wide range of stocks. The rise and fall of stocks on the Tokyo Stock Exchange Prime board showed that the number of decliners exceeded 1,300, affecting the overall market.

Fisco JapanJul 25 03:03 ET